With lung cancer rates among non-smokers rising, especially young East Asian women, a new study released Monday is touting ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

The $78 bln oil major urgently needs a hands-on chair who its new activist can work with. Former BHP Chair Ken MacKenzie, who ...

HONG KONG — Asian shares fell Monday and U.S. futures and the dollar weakened after Moody’sRatings downgraded the sovereign ...

Novo Nordisk is parting ways with its CEO Lars Fruergaard Jørgensen after the two parties mutually agreed that a change of ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

Investing.com -- S&P Global Ratings has upgraded the Denmark-based pharmaceutical company Novo Nordisk (NYSE: NVO) A/S to ’AA’ from ’AA-’ due to its sustainable strong ongoing growth prospects. The ...

Novo Nordisk A/S NVO shares lost 2.7% on Friday after a surprising announcement regarding changes to its executive leadership ...

HealthDay News — Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes, and other metabolic diseases.

Drug manufacturers to focus on China and Japan, where penetration is low and innovation continues to emerge, Morgan Stanley ...

The price of Wegovy, Novo Nordisk’s blockbuster weight-loss drug, is $1,349 a month in the U.S.; in Germany, it’s $328. The U.S. price for Keytruda, a cancer treatment, is $191,000 a year; in Japan, ...

For many CBS viewers, The Equalizer came to an end too soon — but is there a chance Queen Latifah‘s show could return? “It is ...